Pasar al contenido principal

ACIDO OLEANOLICO COMO COADYUVANTE TERAPEUTICO EN EL TRATAMIENTO DE LA DIABETES MELLITUS TIPO 2

PID2019-107837RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oleanolic Acid: Extraction, Characterization and Biological Activity

  • Castellano, José María
  • Ramos-Romero, Sara
  • Perona, Javier S.
29 Páginas.-- 1 Tabla.-- 4 Figuras, Oleanolic acid, a pentacyclic triterpenoid ubiquitously present in the plant kingdom, is receiving outstanding attention from the scientific community due to its biological activity against multiple diseases. Oleanolic acid is endowed with a wide range of biological activities with therapeutic potential by means of complex and multifactorial mechanisms. There is evidence suggesting that oleanolic acid might be effective against dyslipidemia, diabetes and metabolic syndrome, through enhancing insulin response, preserving the functionality and survival of β-cells and pro-tecting against diabetes complications. In addition, several other functions have been proposed, in-cluding antiviral, anti-HIV, antibacterial, antifungal, anticarcinogenic, anti-inflammatory, hepato-protective, gastroprotective, hypolipidemic and anti-atherosclerotic activities, as well as interfering in several stages of the development of different types of cancer; however, due to its hydrophobic nature, oleanolic acid is almost insoluble in water, which has led to a number of approaches to enhance its biopharmaceutical properties. In this scenario, the present review aimed to summarize the current knowledge and the research progress made in the last years on the extraction and characterization of oleanolic acid and its biological activities and the underlying mechanisms of action., This research was funded by the Spanish National Research Agency, grant number PID2019-107837RB-I00, AGL2017-83599-R, PID2020-117009RB-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic Properties and Use of Extra Virgin Olive Oil in Clinical Nutrition: A Narrative Review and Literature Update

  • Jiménez-Sánchez, Andrés
  • Martínez-Ortega, Antonio J.
  • Remón-Ruiz, Pablo
  • Piñar-Gutiérrez, Ana
  • Pereira-Cunill, José Luis
  • García-Luna, Pedro Pablo
Extra virgin olive oil (EVOO) is a cornerstone of the Mediterranean diet (MedD). In this narrative review, we synthesize and illustrate the various characteristics and clinical applications of EVOO and its components-such as oleic acid, hydroxytyrosol, and oleuropein-in the field of clinical nutrition and dietetics. The evidence is split into diet therapy, oleic acid-based enteral nutrition formulations and oral supplementation formulations, oleic acid-based parenteral nutrition, and nutraceutical supplementation of minor components of EVOO. EVOO has diverse beneficial health properties, and current evidence supports the use of whole EVOO in diet therapy and the supplementation of its minor components to improve cardiovascular health, lipoprotein metabolism, and diabetes mellitus in clinical nutrition. Nevertheless, more intervention studies in humans are needed to chisel specific recommendations for its therapeutic use through different formulations in other specific diseases and clinical populations., This article is part of the R+D+i project PID2019-107837RB-I00, funded by MCIN/AEI/10.13039/501100011033/., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Oleanolic acid bioavailability in human serum

  • García-González, Aída
  • Espinosa, Juan M.
  • Cerrillo, Isabel
  • Montero Romero, Emilio
  • Rivas-Melo, Juan José
  • Romero-Báez, Andrea
  • Jiménez-Andreu, María Dolores
  • Ruíz-Trillo, Carmen Amelia
  • Rodríguez-Rodríguez, Ana
  • Martínez-Ortega, Antonio Jesús
  • Roque-Cuellar, María Del Carmen
  • García-Rey, Silvia
  • Jiménez-Sánchez, Andrés
  • Mangas-Cruz, Miguel Ángel
  • Pereira-Cunill, José Luis
  • Perona, Javier S.
  • García-Luna, Pedro Pablo
  • Castellano, José María
[Description of methods used for collection/generation of data] 1. Extraction and GC-MS determination (DOI 10.1002/bmc.3480); 2. UV Spectrophotometry method for OA-HSA association (DOI 10.1021/jf1039537); 3. Enzymatic methods were used to determine serum glucose, total cholesterol, HDL and triglycerides, whereas LDL was estimated by the Friedewald formula (14). Total lipoprotein Apo B (Apo B48 + Apo B100) was quantified by an immunoturbidimetric assay (Tinaquant; Roche Diagnostics, Mannheim, Germany), and serum insulin using an ELISA kit (Diaclone, Besançon, France)., [Methods for processing the data] The variables were expressed as mean ± standard deviation (SD), unless otherwise stated. Differences between the study groups were evaluated by one- or two-way ANOVA, following by Bonferroni´s multiple-comparison test or Kruskal-Wallis test., Evidence of the pharmacological activity of oleanolic acid (OA) suggests its potential therapeutic application. However, its use in functional foods, dietary supplements, or nutraceuticals is hindered by limited human bioavailability studies. The BIO-OLTRAD trial is a double-blind, randomized controlled study with 22 participants that received a single dose of 30 mg OA formulated as a functional olive oil. The study revealed that the maximum serum concentration of OA ranged from 500 to 600 ng/mL, with an AUC0–∞ value of 2862.50 ± 174.50 ng·h/mL. Furthermore, we discovered a physiological association of OA with serum albumin and triglyceride-rich lipoproteins (TRL). UV absorption spectra showed conformational changes in serum albumin due to the formation of an adduct with OA. Additionally, we demonstrated that TRL incorporate OA, reaching a maximum concentration of 140 ng/mL after 2-4 hours. We conjecture that both are efficient carriers to reach target tissues and to yield high bioavailability. This dataset includes the raw data used in the elaboration of the results reported in the article (DOI)., This research is part of the R+D+i project PID2019-107837RB-I00, funded by the Spanish Ministry of Science and Innovation/Spanish Research Agency, grant number MCIN/AEI/10.13039/501100011033/., 1.Row data OA pharmacokinetics in human serum; 2. Raw data OA-HSA association; 3. Row data OA in TRL; 4. Raw data blood biochemistry, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bioavailability and systemic transport of oleanolic acid in humans, formulated as a functional olive oil

  • García-González, Aída
  • Espinosa, Juan M.
  • Cerrillo, Isabel
  • Montero Romero, Emilio
  • Rivas-Melo, Juan José
  • Romero-Báez, Andrea
  • Jiménez-Andreu, María Dolores
  • Ruíz-Trillo, Carmen Amelia
  • Rodríguez-Rodríguez, Ana
  • Martínez-Ortega, Antonio Jesús
  • Roque-Cuellar, María Del Carmen
  • García-Rey, Silvia
  • Jiménez-Sánchez, Andrés
  • Mangas-Cruz, Miguel Ángel
  • Pereira-Cunill, José Luis
  • Perona, Javier S.
  • García-Luna, Pedro Pablo
  • Castellano, José María
14 Páginas.-- 6 Figuras.-- 2 Tablas, Evidence of the pharmacological activity of oleanolic acid (OA) suggests its potential therapeutic application. However, its use in functional foods, dietary supplements, or nutraceuticals is hindered by limited human bioavailability studies. The BIO-OLTRAD trial is a double-blind, randomized controlled study with 22 participants that received a single dose of 30 mg OA formulated as a functional olive oil. The study revealed that the maximum serum concentration of OA ranged from 500 to 600 ng mL-1, with an AUC0-∞ value of 2862.50 ± 174.50 ng h mL-1. Furthermore, we discovered a physiological association of OA with serum albumin and triglyceride-rich lipoproteins (TRL). UV absorption spectra showed conformational changes in serum albumin due to the formation of an adduct with OA. Additionally, we demonstrated that TRL incorporate OA, reaching a maximum concentration of 140 ng mL-1 after 2-4 hours. We conjecture that both are efficient carriers to reach target tissues and to yield high bioavailability., This research is part of the R+D+i project PID2019-107837RB-I00, funded by the Spanish Ministry of Science and Innovation/Spanish National Research Agency, grant number MCIN/AEI/10.13039/501100011033/. A. G.-G. is grateful for funding received from the “Next Generation EU” funds, the European Union through the Recovery, Transformation and Resilience Plan and by the Ministry of Universities, in the framework of the Margarita Salas, Maria Zambrano grants for the Requalification of the Spanish University System 2021–2023, organized by the Pablo de Olavide University, Seville. J. J. R.-M. obtained an Erasmus+ scholarship (No. 2021-1-IT02-KA131-HED-000008483) from the University of Sassari (ITALY), for a stay at the Department of Food and Health of the Instituto de la Grasa-CSIC. The authors especially thank the ACESUR Group (Dos Hermanas, Seville, Spain), which donated the commercial olive oil for the trial. This collaborator had no role in the design, collection, analysis or interpretation of the data or in the decision to submit the manuscript for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Safety of a long-term intervention with oleanolic acid in type 2 diabetes patients

  • Castellano, José María
[Methods for processing the data] All analyses were conducted on an intention-to-treat basis. The Kolmogorov–Smirnov test was performed to assess the distribution of quantitative variables. Continuous variables that significantly deviated from the assumption of normality were transformed accordingly. Continuous variables are presented as mean ± standard deviation, while categorical variables are presented as proportions. ?changes were calculated as changes produced between post- and pre-intervention (the value after 12-months of intervention minus value at baseline). Categorical variables were compared using Chi-square tests. Within-group and between-group changes were assessed using paired and unpaired t tests, respectively. To evaluate data variation according to intervention group and time (baseline to 12 months), repeated-measures ANOVA was conducted, followed by post-hoc multiple comparisons analysis using the Bonferroni correction. Analyses were adjusted for potential confounders or effect modifiers (age, sex, and BMI), except when the variable of interest already incorporated one or more of these covariates in its definition, in which case adjustments were not applied to avoid redundancy., Oleanolic acid (OA), a plant-derived triterpene, has demonstrated anti-inflammatory and antidiabetic properties in preclinical models. However, concerns regarding its long-term safety in humans persist due to limited clinical data and conflicting results from animal research. This study evaluated the long-term safety and tolerability of OA therapeutic doses, formulated as OA-enriched olive oil, in patients with type 2 diabetes mellitus (T2DM), a population at high cardiometabolic risk. In this 12-month, double-blind, randomized pilot trial (n = 50), participants consumed either OA-enriched olive oil (600 mg OA/kg oil; 30 mg OA/day) or the same oil not reinforced in OA (control olive oil). Clinical safety was assessed through serum markers of liver and kidney function, coagulation parameters, and systemic inflammation. Non-invasive indices for hepatic steatosis and fibrosis were also calculated. The OA-enriched intervention was well tolerated, with no significant adverse changes in hepatic or renal biomarkers. The OA group, but not the control group, showed improved kidney function, including reduced serum creatinine concentration (-6.1% compared to baseline) and increased estimated glomerular filtration rate (5.3% compared to baseline) (p < 0.05). Hepatic enzyme levels remained stable, and no progression in liver steatosis or fibrosis scores was observed. Coagulation markers remained within normal ranges in both groups with no significant adverse events attributed to OA intake. These findings are derived from a pilot trial , and, therefore, larger studies should be necessary to confirm the results and assess their generalizability. Nonetheless, our outcomes provide an unprecedented clinical evidence that long-term consumption of OA-enriched olive oil, providing a highly bioavailable therapeutic dose of the triterpene, is safe and well tolerated by T2DM patients, underscoring its long-term feasibility and sustainability. The intervention may confer additional renal and metabolic benefits, supporting its potential as a functional food strategy in the management of chronic metabolic diseases. This dataset includes the raw data used in the elaboration of the results reported in the article (in press)., This research is part of the R+D+i project PID2019-107837RB-I00, funded by the Spanish Ministry of Science and Innovation/Spanish National Research Agency, grant number MCIN/AEI/10.13039/501100011033/., OA_safety.csv, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

The OLTRAD Study (I): Clinical efficacy

  • Matamoros-Domínguez, Alejandro
  • Espinosa-Cabello, Juan M.
  • García-González, Aída
  • León-Aranda, Manuel Jesús
  • Pérez-Muñoz, Gisela
  • Jiménez-Sánchez, Andrés
  • Martínez-Ortega, Antonio Jesús
  • García-Rey, Silvia
  • Roque-Cuellar, María Del Carmen
  • Piñar-Gutiérrez, Ana
  • Ruíz-Trillo, Carmen Amelia
  • Mangas-Cruz, Miguel Ángel
  • Pereira-Cunill, José Luis
  • Cerrillo, Isabel
  • Yubero-Serrano, Elena María
  • Perona, Javier S.
  • García-Luna, Pedro Pablo
  • Castellano, José María
[Description of methods used for collection/generation of data] Design overview The OLTRAD study was a randomized, parallel-group, double-blinded, and placebo-controlled superiority trial conducted at the Endocrinology and Nutrition Service of the Virgen del Roc o University Hospital (Seville, Spain) between February 2022 and March 2025. The trial was designed to demonstrate that the regular intake of a functional olive oil enriched in OA may be effective as an adjuvant to the pharmacological therapy with metformin and other conventional antidiabetic drugs. Participants were randomly assigned to one of two study groups: OA-enriched olive oil (intervention group) or the same olive oil not reinforced with the triterpene (control oil) for a 12-month follow-up period. Settings and Participants Eligible participants complied with all the following criteria: 1) community-residing men and women aged 18-75 years; 2) Body Mass Index (BMI) between 25.0 and 39.9 kg/m2; 3) diagnosed with T2DM at least six months before enrollment [following the American Diabetes Association (ADA) 2019 criteria]; 4) treated with metformin (stable dose ? 850 mg/day at least three months before recruitment) as monotherapy or in combination with other hypoglycemic agents, except pioglitazone and sulphonylureas; 5) Glycated hemoglobin (HbA1c) <9% at screening, , with a variation of 0.5% in the three months prior to inclusion; 6) ability to provide written informed consent; and 7) willingness to comply with study procedures. The candidates to participate were excluded if they have at the recruitment time any of the following criteria: 1) Diagnosis of type 1 diabetes or latent autoimmune diabetes (LADA) in adults; 2) chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR)<30 mL/min/1.73m ]; 3) acute or chronic hepatitis, or other liver diseases [excluding Metabolic dysfunction-Associated Steatosis Liver Disease (MASLD)], or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times upper limit of reference range; 4) food allergies or intolerances relevant to the intervention; 5) pregnancy or lactation; 6) women of childbearing potential unwilling to use effective contraception; 7) fasting triglycerides >600 mg/dL despite treatment; 8) grade 3 hypertension [systolic blood pressure (SBP)?180 mmHg and/or diastolic blood pressure (DBP) ?110 mmHg]; 9) use of pioglitazone or sulfonylureas; 10) use of weight-loss medications other than GLP-1RA, provided that the GLP-1RA indication was a T2DM diagnosis, the drug use was chronic (defined as 12 months or more prior to enrollment), and the participant's weight remained stable (defined as body weight variations of up to 5% in the 6 months prior to enrollment); 11) chronic systemic corticosteroid use (>14 days) in the previous 6 months (excluding topical/inhaled forms); 12) major cardiovascular events within the past 6 months (e.g., myocardial infarction, unstable angina, NYHA class III IV heart failure, stroke); 13) uncontrolled endocrine disorders (e.g., thyrotoxicosis, adrenal crisis); 14) history of an active or untreated malignancy, or are in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) during the last 5 years prior to study entry; 15) participation in another clinical trial in the past 30 days (or longer if prior investigational drug had a long half-life); 16) concurrent enrollment in any other interventional clinical study deemed incompatible by the investigators; 17) hematologic conditions interfering with HbA1c measurement (e.g., hemolytic anemia, sickle cell disease); and 18) any other medical, psychiatric, or substance-related condition that, in the investigator s opinion, could interfere with study adherence or completion. Intervention and follow-up At the time of recruitment and quarterly thereafter, participants were subjected to anthropometric, blood pressure, and heart rate measurements. They were also asked about their perception of their own health status, and fill in a questionnaire about lifestyle, medical conditions and use of medication. In addition, body composition analysis was carried out by electrical bioimpedance (Tanita BC 420 S MA; West Drayton, UK). Also, at baseline and every three months afterwards, fasting blood samples were withdrawn from the median cubital vein and collected in sterile plastic tubes with vacuum system. Conventional analytical determinations in blood and urine were performed in the Laboratory of Analysis and Clinical Biochemistry of the Virgen del Roc o University Hospital of Seville following standard operating procedures. Outcomes Anthropometric measurements and clinical examination Participants underwent a comprehensive clinical evaluation including measurement of anthropometric parameters (BMI, height and waist circumference), pulse and blood pressure (SBP and DBP). In addition, body composition analysis was carried out by electrical bioimpedance, and Fat Mass Index (FMI) was calculated as total fat mass (kg) divided by the square of height (m ) and expressed in kg/m . Blood biochemistry In samples of cubital blood we realized cell count and determinations related to circulating lipids [total triglycerides (TG), total cholesterol (TC), low density lipoprotein-associated cholesterol (LDL-c), high density lipoprotein-associated cholesterol (HDL-c), total apolipoprotein B]; glucose homeostasis [glycemia, insulinemia, C peptide, glycated haemoglobin (HbA1c)]; oxidative stress and inflammation [ultra-sensitive C-reactive protein], as well as associated to liver and kidney injury [hepatic transaminases (ALT, AST, GGT), and creatinine]. Serum creatinine (sCr)-based estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi (chronic kidney disease epidemiology collaboration) equation. Medication use Concomitant medication, including metformin dosage, as well as the use of GLP-1 receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, was obtained from the participants' electronic medical records and self-completed questionnaires, reflecting the individualized pharmacological management of each of them. Determination of serum OA concentration The identification and quantification of OA in the serum were performed using a gas chromatography mass spectrometry (GC-MS) system, following a modification of the method previously established and validated in our laboratory [DOI 10.1002/bmc.3480]. Briefly, 15 ?L of betulinic acid (internal standard, 0.1 mg/mL in methanol) were added to 1 mL of serum. After the methanol removal by vacuum, the sample was filtered (0.20 ?m) and extracted with 3.0 mL of 5% isopropyl alcohol in diethyl ether (3 min vortexing and centrifugation at 1620 g, 10 min at 20 0C; repeated 3x). The combined supernatant was dried, and the residue was resuspended and derivatized with BSTFA [N,O-bis-(trimethylsilyl) trifluoroacetamide +1% TMCS (trimethylchlorosilane)] in pyridine (1:1 v/v), assisted by ultrasound (70 W; 40 C, 15 min). A 1 ?L aliquot of the derivatized sample was then injected and analyzed by GC-MS., [Methods for processing the data] All statistical analyses were performed using JASP version 0.98.1 (JASP Team, University of Amsterdam, Amsterdam, Netherlands). Continuous variables following a normal distribution were expressed as mean standard deviation, whereas those showing a non-normal, skewed distribution were expressed as the median and interquartile range (25th and 75th percentiles). Categorical variables are expressed as absolute and relative frequencies. Initial comparisons between groups were conducted using Student's t-test or the Mann-Whitney U test for continuous variables, depending on the data distribution, and Fisher's exact test for categorical variables. The primary outcome for each clinical parameter was defined as the 12-month change from baseline (? = T12 ? T0). The effect of treatment on each ? variable was assessed using linear regression-based analysis of covariance (ANCOVA), adjusted for baseline value, age and sex. Normality of residuals and homoscedasticity were assessed for each model using Shapiro-Wilk and Levene's tests, respectively; both assumptions were adequately met across all models, and no non-parametric alternatives were required. In addition to the primary analysis, exploratory post-hoc subgroup analyses examined whether the treatment effect was modified by baseline metformin dose, fat mass index (FMI), or concomitant use of GLP-1 RA and iSGLT2, through four separate interaction models, each incorporating a group effect-modifier term alongside the baseline covariates: Model 1 (metformin dose): ? variable as the dependent variable; baseline value, age, sex, and continuous BMI as covariates; treatment group, metformin dose (<2000 vs ?2000 mg/day), and GLP-1RA use as factors; group metformin dose as the interaction term. Model 2 (FMI): ? variable as the dependent variable; baseline value, age, sex, and continuous metformin dose as covariates; treatment group, FMI category, and GLP-1RA use as factors; group FMI as the interaction term. FMI was categorized as low or high using sex-specific cutoffs of 9 kg/m for men and 13 kg/m for women, consistent with previously published thresholds for excess adiposity based on fat mass index [66]. Model 3 (GLP-1 RA use): ? variable as the dependent variable; baseline value, age, sex, continuous metformin dose, and continuous FMI as covariates; treatment group and GLP-1RA use as factors; group GLP-1 RA use as the interaction term. Model 4 (iSGLT2 use): ? variable as the dependent variable; baseline value, age, sex, continuous metformin dose, and continuous FMI as covariates; treatment group and iSGLT2 use as factors; group iSGLT2 use as the interaction term. For each model, effect estimates (?) and 95% confidence intervals for OA-enriched oil versus control were extracted within each level of the effect modifier, together with the corresponding p-value for interaction. No correction for multiple comparisons was applied. A two-sided p < 0.05 was considered statistically significant throughout, except for the sample size calculation, which used a one-sided test., This research is part of the R+D+i project PID2019-107837RB-I00, funded by the Spanish Ministry of Science and Innovation/Spanish State Research Agency (Agencia Estatal de Investigacion, AEI) (MCIN/AEI/10.13039/501100011033/). Alejandro Matamoros-Dominguez is grateful for funding received from the Andalusian Regional Government/Regional Ministry of University, Research and Innovation and the European Social Fund Plus (ESF+) (DGP_PRED_2024_00736). A da Garcia-Gonzalez is grateful for funding received from the European Union through the Next Generation EU funds and the Recovery, Transformation and Resilience Plan, and by the Ministry of Universities, in the framework of the Margarita Salas, Maria Zambrano grants for the Requalification of the Spanish University System 2021 2023, organized by the Pablo de Olavide University, Seville. Andres Jimenez Sanchez is supported by a Rio Hortega contract (CM25/00251) from the Instituto de Salud Carlos III (ISCIII), co-funded by the European Union., Datos-crudos-OLTRAD-1.xlsx, Peer reviewed